APO-TRANDOLAPRIL 1 MG
TRANDOLAPRIL : 1 MG · DIN 02487195 · APOTEX INC
Health Canada status: APPROVED
What is APO-TRANDOLAPRIL?
APO-TRANDOLAPRIL 1 MG contains TRANDOLAPRIL : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02487195, held by APOTEX INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as approved, status dated 08-Apr-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-TRANDOLAPRIL used for?
Treatment of Mild to Moderate Essential Hypertension. Treatment Following Acute Myocardial Infarction in clinically stable patients with left ventricular dysfunction.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02487195 |
|---|---|
| Brand name | APO-TRANDOLAPRIL |
| Generic / active ingredient | TRANDOLAPRIL : 1 MG |
| Manufacturer | APOTEX INC |
| Strength | 1 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA10 TRANDOLAPRIL |
| AHFS class | 24:32.04 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 08-Apr-2019 |
How is it administered?
Hypertension: 1-2 mg once daily (max 4 mg). Post-MI: Start at 0.5 mg on day 3, titrate to 4 mg once daily. Start under medical supervision. Dose adjustments for renal/hepatic impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents lists section 11, but text ends before section). Typical ACE inhibitor storage is 15-30°C.
How is it supplied?
Not explicitly detailed in provided text (mentions 0.5 mg, 1 mg, 2 mg and 4 mg strengths).
Contraindications
Pregnancy/nursing; hypersensitivity to ACE inhibitors; history of angioedema; use with sacubitril/valsartan, aliskiren, or ARBs in specific patients; hereditary galactose intolerance; hypotension.
Warnings and precautions
Serious Warning: Fetal toxicity. Risk of angioedema (can be fatal), hypotension, hyperkalemia, neutropenia/agranulocytosis, and impaired renal function. Caution in aortic stenosis.
Is TRANDOLAPRIL in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by PRO DOC LIMITEE, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C09AA10 TRANDOLAPRIL. 25 of 40 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-TRANDOLAPRIL | 0.5 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02471868 |
| AURO-TRANDOLAPRIL | 1 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02471876 |
| AURO-TRANDOLAPRIL | 2 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02471884 |
| AURO-TRANDOLAPRIL | 4 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02471892 |
| MAVIK | 0.5 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 02231457 |
| MAVIK | 1 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 02231459 |
| MAVIK | 2 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 02231460 |
| MAVIK | 4 MG | CAPSULE | BGP PHARMA ULC | MARKETED | DIN 02239267 |
| PMS-TRANDOLAPRIL | 0.5 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02357755 |
| PMS-TRANDOLAPRIL | 1 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02357763 |
Who else supplies TRANDOLAPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRANDOLAPRIL appears in 156 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.